MaaT Pharma to Hold Annual General Meeting on May 28, 2024
April 22 2024 - 12:00PM
Business Wire
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage
biotechnology company and a leader in the development of Microbiome
Ecosystem TherapiesTM (MET) dedicated to enhancing survival for
patients with cancer, informs its shareholders that the Annual
General Meeting (ordinary and extraordinary) will be held on May,
28, 2024, at 11:00 a.m. CET at the Company’s headquarter in France
located at 70 avenue Tony Garnier, 69007 Lyon.
The notice of meeting, serving as convening notice was published
in the Bulletin des annonces légales obligatoires on Monday, 22
April 2024 (www.journal-officiel.gouv.fr/balo), in bulletin no. 49
(reference 2400937). It contains the detailed agenda, the draft
resolutions and the main terms and conditions of participation and
voting at this meeting.
The convening notice will be published in the Journal des
annonces légales "Le Tout Lyon" on 6 May 2024. It will also be sent
to registered shareholders and made available to institutions
holding bearer shares.
The documents and information relating to this General Meeting
have been and will be, in accordance with the applicable laws and
regulations:
- posted on MaaT Pharma's website
(https://www.maatpharma.com/investors/#GM) under the section
"Investors/General Meetings/2024";
- made available to shareholders at the Company's registered
office at 70 avenue Tony Garnier, 69007 Lyon, France;
- and sent to shareholders by Uptevia - Service Assemblées
Générales, 90 - 110 Esplanade du Général de Gaulle - 92931 Paris La
Défense Cedex, on receipt of their request.
Further information on this General Meeting, and on how
shareholders can vote, is available at
https://www.maatpharma.com/investors/#GM ("Participating in the
General Meeting").
About MaaT Pharma
MaaT Pharma, a leading clinical-stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma initiated an
open-label, single-arm Phase 3 clinical trial in patients with
acute GvHD, building on the positive results of its Phase 2
proof-of-concept study. Its powerful discovery and analysis
platform, gutPrint®, enables the identification of novel disease
targets, evaluation of drug candidates, and identification of
biomarkers for microbiome-related conditions. The company’s
Microbiome Ecosystem Therapies are produced through a standardized
cGMP manufacturing and quality control process to safely deliver
the full diversity of the microbiome in liquid and oral
formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice. MaaT Pharma is listed on Euronext
Paris (ticker: MAAT).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240422348155/en/
MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D.
Head of Investor Relations +33 6 16 48 92 50
invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 14 06 45 92
media@maat-pharma.com
Trophic Communications Jacob VERGHESE or Priscillia
PERRIN +49 151 7441 6179 maat@trophic.eu
Maat Pharma (EU:MAAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maat Pharma (EU:MAAT)
Historical Stock Chart
From Jul 2023 to Jul 2024